-
Mashup Score: 3Aficamten Shows Promise in Difficult to Treat Non-Obstructive Hypertrophic Cardiomyopathy - 1 year(s) ago
Data from cohort 4 in REDWOOD-HCM provides the first insight into the effects of aficamten in a cohort of patients with non-obstructive hypertrophic cardiomyopathy.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Mary McGowan, MD, discusses a study she presented examining the overall prevalence of patients with high-risk hypercholesterolemia who fail to meet guideline-recommended goals for LDL-C levels.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
New data presented at #ACC2023 suggests more than 70% of high-risk patients with hypercholesterolemia never reach guideline-recommended LDL-C levels. Learn more and hear from Mary McGowan, MD, of @TheFHFoundation: https://t.co/7cYuxaeY5a #Cholesterol #LDL
-
-
Mashup Score: 4American College of Cardiology - 1 year(s) ago
HCPLive is a comprehensive clinical news and information portal that provides physicians with up-to-date specialty and disease-specific resources designed to help them provide better care to patients. At HCPLive, you will find breaking news, video interviews with physician experts, in-depth conference coverage, finance and practice management updates, insight and analysis from physician…
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
#ACC2023 officially comes to a close with the @ACCinTouch convocation ceremony. Best of luck to the future leaders of cardiovascular care! Catch up on anything you may have missed from the conference by heading over to our conference coverage page: https://t.co/4bwQZ6Sg7J https://t.co/J2n3dtaxps
-
-
Mashup Score: 0STELLAR: Sotatercept Improves Function, Alleviates Disease Burden in Pulmonary Arterial Hypertension - 1 year(s) ago
Data from the phase 3 STELLAR trial indicate adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial’s 9 secondary endpoints, including time to death or clinical worsening.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
The phase 3 STELLAR trial indicates adding sotatercept to background therapy in PAH was associated with statistically significant improvements in 6-minute walk distance and 8 of the trial's 9 secondary endpoints. https://t.co/YmmsdRStIP #ACC2023 #Hypertension
-
-
Mashup Score: 0Coordinated, Multidisciplinary Approach Can Dramatically Improve GDMT Prescription for Type 2 Diabetes - 1 year(s) ago
Data from COORDINATE-Diabetes presented at ACC 2023 demonstrate the impact of a multifaceted, coordinated care approach on improving prescription rates of statins, ACEs/ARBs, and glucose-lowering medications among people with type 2 diabetes.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Learn more about COORDINATE-Diabetes and how a multifaceted, multidisciplinary approach to care can improve GDMT uptake among people with type 2 diabetes: https://t.co/kQqm1Lh2AV #T2D #ACC2023
-
-
Mashup Score: 2Atrial Pacing for Chronotropic Incompetence in HFpEF - 1 year(s) ago
This randomized crossover trial assessed if implanting and programming a pacemaker for rate-adaptive atrial pacing improved exercise performance in patients with heart failure with preserved ejection fraction and chronotropic incompetence at a single US tertiary referral center.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
3rd wrap-up from #ACC2023 with significant impact clinical practice: ❤️🔥 #RAPID_HF 👉P.M. implantantion in #HFpEF with chronotropic incompetence didn’t ⬆️ Exercise capacity, Symptoms & ❤️ output 🔴 ⬆️ in AE @JJheart_doc @hvanspall @gcfmd @RFE_Pedretti https://t.co/83gJi5ezEf https://t.co/O4JLK2UywC
-
-
Mashup Score: 10
Intensified LDL-lowering upped fibrous cap thickness on OCT and cut lipid burden on NIRS. Next up: biomarkers to predict effects.
Source: TCTMD.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @mmamas1973: #ACC2023 @TCTMD overview of YELLOW-3 @ShelleyWood2 ➡️https://t.co/Vhypljeq19 empaglifozocin reduces TCFA phenotype and plaq…
-
-
Mashup Score: 1Cncf – Collège National des Cardiologue Français - 1 year(s) ago
LE SYNDROME D’APNÉES DU SOMMEIL TOUT SAVOIR SUR LA FIBRILLATION AURICULAIRE Consultez nos derniers…
Source: cncf.euCategories: Cardiologists, Latest HeadlinesTweet-
#LOADSTAR #LBCT #LLT at #ACC23 #ACC2023 residual risk, target or magnitude of #LDL decrease? See videos at https://t.co/zxbmeWAOX3 https://t.co/2SgHlLJ3Dm
-
-
Mashup Score: 0
Steve Nissen, MD, sits down for an interview to discuss the clinical takeaways, design intricacies, safety signals, and more from the CLEAR Outcomes trial.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
From the conference floor: Hear from Steve Nissen, MD, as he discusses his top takeaways from CLEAR Outcomes as well as some of the intricacies of trial design, including the determination of statin intolerance used in the trial. Learn more: https://t.co/6nV4Yvyqx4 #ACC2023
-
-
Mashup Score: 0Don't Miss a Beat: Top Takeaways from NUDGE FLU at ACC 2023 - 1 year(s) ago
Hosts are joined by Tor Biering-Sørenson, MD, MSc, MPH, PhD, to discuss the NUDGE FLU trial and how the lessons learned can inform implementation strategies for various other types of therapies.
Source: HCP LiveCategories: General Medicine News, Latest HeadlinesTweet-
Interested in learning more about NUDGE FLU? Check out this special edition episode of #DontMissABeat from #ACC2023 with lead investigator Prof. Tor Biering-Sørenson: https://t.co/iFNvAu5t9Y #Cardiology #Influenza
-
Check out this interview with @MasriAhmadMD at #ACC2023 where he provides further insight into the results of the REDWOOD-HCM cohort 4, which included 41 patients with non-obstructive hypertrophic cardiomyopathy. https://t.co/AJrIXMDrB2 #Cardiology #HCM